Ident. | Authors (with country if any) | Title |
---|
000000 |
Alexandro Gianforcaro [Canada] ; Mazen J. Hamadeh [Canada] | Vitamin D as a Potential Therapy in Amyotrophic Lateral Sclerosis |
000003 |
Stéphanie Bissonnette [Canada] ; Sophie Muratot [Canada] ; Nathalie Vernoux [Canada] ; François Bezeau [Canada] ; Frédéric Calon [Canada] ; Sébastien S. Hebert [Canada] ; Pershia Samadi [Canada] | The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease |
000010 |
YOUN JU LEE [Corée du Sud] ; So-Young Choi [Corée du Sud] ; Jae H. Yang [Corée du Sud] | NMDA receptor-mediated ERK 1/2 pathway is involved in PFHxS-induced apoptosis of PC12 cells |
000014 |
Nicolas Morin [Canada] ; Vincent A. Jourdain ; Thérèse Di Paolo | Modeling dyskinesia in animal models of Parkinson disease : ANIMAL MODELS OF PARKINSON'S DISEASE |
000027 |
JINGYI MA [Canada] ; L. Stan Leung [Canada] | Deep brain stimulation of the medial septum or nucleus accumbens alleviates psychosis-relevant behavior in ketamine-treated rats |
000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
000082 |
Maria Gabriela Sanchez [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys |
000083 |
Alexander C. Sutton [États-Unis] ; Wilson Yu [États-Unis] ; Megan E. Calos [États-Unis] ; Lauren E. Mueller [États-Unis] ; Matthew Berk [États-Unis] ; Jenny Shim [États-Unis] ; Eric S. Molho [États-Unis] ; Jonathan M. Brotchie [Canada] ; Peter L. Carlen [Canada] ; Damian S. Shin [États-Unis] | Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat |
000086 |
Scott Mackey [États-Unis, Canada] ; YU JING [République populaire de Chine, Canada] ; Joseph Flores [Suède, Canada] ; Katie Dinelle [Canada] ; Doris J. Doudet [Canada] | Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry |
000088 |
Lily R. Aleksandrova [Canada] ; Meaghan C. Creed [Canada] ; Paul J. Fletcher [Canada] ; Daniela S. S. Lobo [Canada] ; Clement Hamani [Canada] ; José N. Nobrega [Canada] | Deep brain stimulation of the subthalamic nucleus increases premature responding in a rat gambling task |
000115 |
D. Domenger [Canada] ; D. Dea [Canada] ; L. Theroux [Canada] ; L. Moquin [Canada] ; A. Gratton [Canada] ; J. Poirier [Canada] | The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain |
000147 |
Marie-Anne El Khoury [France] ; Victor Gorgievski [France] ; Larissa Moutsimilli [France] ; Bruno Giros [France, Canada] ; Eleni T. Tzavara [France] | Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies |
000164 |
D. W. Luchtman [Canada] ; Q. Meng [Canada] ; C. Song [Canada, République populaire de Chine] | Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease |
000165 |
Anne Almey [Canada] ; Edward J. Filardo [États-Unis] ; Teresa A. Milner [États-Unis] ; Wayne G. Brake [Canada] | Estrogen Receptors Are Found in Glia and at Extranuclear Neuronal Sites in the Dorsal Striatum of Female Rats: Evidence for Cholinergic But Not Dopaminergic Colocalization |
000175 |
S. Al-Sweidi [Canada] ; M. Morissette [Canada] ; T. Di Paolo [Canada] | Effect of Oestrogen Receptors on Brain NMDA Receptors of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mice |
000194 |
M. Anne Harris [Canada] ; Joseph K. Tsui [Canada] ; Stephen A. Marion [Canada] ; HUI SHEN [Canada] ; Kay Teschke [Canada] | Association of Parkinson's Disease With Infections and Occupational Exposure to Possible Vectors |
000214 |
Darcy Litteljohn [Canada] ; Eric Nelson [Canada] ; Cheri Bethune [Canada] ; Shawn Hayley [Canada] | The effects of paraquat on regional brain neurotransmitter activity, hippocampal BDNF and behavioural function in female mice |
000226 |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease |
000244 |
C. K. Young [Canada] ; I. Q. Whishaw [Canada] ; B. H. Bland [Canada] | POSTERIOR HYPOTHALAMIC NUCLEUS DEEP BRAIN STIMULATION RESTORES LOCOMOTION IN RATS WITH HALOPERIDOL-INDUCED AKINESIA BUT NOT SKILLED FORELIMB USE IN PELLET REACHING AND LEVER PRESSING |
000262 |
Andrew R. Brown [Canada] ; Michael C. Antle [Canada] ; BIN HU [Canada] ; G. Campbell Teskey [Canada] | High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats |
000276 |
Alexander Klein [Canada] ; Darryl C. Gidyk [Canada] ; Alexandra M. Shriner [Canada] ; Keri L. Colwell [Canada] ; Nadine A. Tatton [Canada] ; William G. Tatton [Canada] ; Gerlinde A. Metz [Canada] | Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: A cautionary note |
000287 |
Sara Kost [Canada] ; CHAO SUN [Canada] ; WEI XIONG [Canada] ; Kathryn Graham [Canada] ; Carol E. Cass [Canada] ; James D. Young [Canada] ; Benedict C. Albensi [Canada] ; Fiona E. Parkinson [Canada] | Behavioral effects of elevated expression of human equilibrative nucleoside transporter 1 in mice |
000308 |
Marc Morissette [Canada] ; Pershia Samadi [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Nancy Belanger [Canada] ; Thérèse Di Paolo [Canada] | Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys |
000316 |
Robert A. Hodgson [États-Unis] ; Paul J. Bedard [Canada] ; Geoffrey B. Varty [États-Unis] ; Tatiana M. Kazdoba [États-Unis] ; Therese Di Paolo [Canada] ; Michael E. Grzelak [États-Unis] ; Annamarie J. Pond [États-Unis] ; Abdallah Hadjtahar [Canada] ; Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; Aurelie Dare [Canada] ; Bernard R. Neustadt [États-Unis] ; Andrew W. Stamford [États-Unis] ; John C. Hunter [États-Unis] | Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders |
000329 |
Jon F. Davis [États-Unis] ; Maarten Loos [États-Unis] ; Andrea R. Di Sebastiano [Canada] ; Jennifer L. Brown [États-Unis] ; Michael N. Lehman [États-Unis, Canada] ; Lique M. Coolen [États-Unis, Canada] | Lesions of the Medial Prefrontal Cortex Cause Maladaptive Sexual Behavior in Male Rats |
000358 |
QINGJIA MENG [Canada] ; Dirk W. Luchtman [Canada] ; BOUCHAIB EL BAHH [Canada] ; Jeffrey A. Zidichouski [Canada] ; JUN YANG [Canada] ; CAI SONG [Canada] | Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices |
000398 |
Andrew R. Brown [Canada] ; BIN HU [Canada] ; Bryan Kolb [Canada] ; G. Campbell Teskey [Canada] | Acoustic tone or medial geniculate stimulation cue training in the rat is associated with neocortical neuroplasticity and reduced akinesia under haloperidol challenge |
000403 |
Alexander Klein [Canada, Allemagne] ; Johanna Wessolleck [Allemagne] ; Anna Papazoglou [Allemagne] ; Gerlinde A. Metz [Canada] ; Guido Nikkhah [Allemagne] | Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats |
000404 |
Desirae M. Haluk [Canada] ; Stan B. Floresco [Canada] | Ventral Striatal Dopamine Modulation of Different Forms of Behavioral Flexibility |
000409 |
Grace Lee [Canada] ; Tony Chu [Canada] ; Christopher A. Shaw [Canada] | The primary locus of motor neuron death in an ALS-PDC mouse model |
000473 |
R. J. Grant [Canada] ; L. H. L. Sellings [Canada] ; S. J. Crocker [États-Unis] ; E. Melloni [Italie] ; D. S. Park [Canada] ; P. B. S. Clarke [Canada] | EFFECTS OF CALPAIN INHIBITION ON DOPAMINERGIC MARKERS AND MOTOR FUNCTION FOLLOWING INTRASTRIATAL 6-HYDROXYDOPAMINE ADMINISTRATION IN RATS |
000483 |
C. K. Young [Canada] ; S. J. Koke [Canada] ; Z. H. Kiss [Canada] ; B. H. Bland [Canada] | DEEP BRAIN STIMULATION OF THE POSTERIOR HYPOTHALAMIC NUCLEUS REVERSES AKINESIA IN BILATERALLY 6-HYDROXYDOPAMINE-LESIONED RATS |
000491 |
Dirk W. Luchtman [Canada] ; DI SHAO [Canada] ; CAI SONG [Canada] | Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease |
000492 |
N. M. Jadavji [Canada] ; G. A. Metz [Canada] | BOTH PRE-AND POST-LESION EXPERIENTIAL THERAPY IS BENEFICIAL IN 6-HYDROXYDOPAMINE DOPAMINE-DEPLETED FEMALE RATS |
000571 |
K. Mukhida [Canada] ; M. Hong [Canada] ; G. B. Miles [Canada] ; T. Phillips [Canada] ; B. A. Baghbaderani [Canada] ; M. Mcleod [Canada] ; N. Kobayashi [Canada] ; A. Sen [Canada] ; L. A. Behie [Canada] ; R. M. Brownstone [Canada] ; I. Mendez [Canada] | A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats |
000594 |
Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
000595 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
000596 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
000611 |
Michelle R. Ciucci [États-Unis] ; Sean T. Ma [États-Unis] ; Cynthia Fox [États-Unis] ; Jacqueline R. Kane [États-Unis] ; Lorraine O. Ramig [États-Unis] ; Timothy Schallert [États-Unis] | Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol : A preliminary study |
000622 |
Frédéric Calon [Canada] ; Greg Cole [États-Unis] | Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases : Evidence from animal studies |
000632 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
000633 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
000642 |
A. Y. Alemdar [Canada] ; D. Sadi [Canada] ; V. Mcalister [Canada] ; I. Mendez [Canada] | Intracerebral Co-transplantation of liposomal tacrolimus improves xenograft survival and reduces graft rejection in the hemiparkinsonian rat |
000646 |
Vesna Sossi [Canada] ; James E. Holden [États-Unis] ; Geoffrey J. Topping [Canada] ; Marie-Laure Camborde [Canada] ; Rich A. Kornelsen [Canada] ; Siobhan E. Mccormick [Canada] ; Jennifer Greene [Canada] ; Andrei R. Studenov [Canada] ; Thomas J. Ruth [Canada] ; Doris J. Doudet [Canada] | In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD |
000648 |
D. S. Shin [Canada] ; M. Samoilova [Canada] ; M. Cotic [Canada] ; L. Zhang [Canada] ; J. M. Brotchie [Canada] ; P. L. Carlen [Canada] | High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleus |
000651 |
Elissa M. Strome [Canada] ; Athanasios P. Zis [Canada] ; Doris J. Doudet [Canada] | Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats |
000690 |
Martine Saint-Pierre [Canada] ; Marie-Eve Tremblay [Canada] ; Attila Sik [Canada] ; Robert E. Gross [États-Unis] ; Francesca Cicchetti [Canada] | Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats |
000695 |
Evelyn F. Field [Canada] ; Gerlinde A. Metz [Canada] ; Sergio M. Pellis [Canada] ; Ian Q. Whishaw [Canada] | Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease |
000697 |
J. Miklossy [Canada] ; D. D. Doudet [Canada] ; C. Schwab [Canada] ; S. Yu [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Role of ICAM-1 in persisting inflammation in parkinson disease and MPTP monkeys |
000701 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
000709 |
Rohita Sharma [Canada] ; Catherine R. Mcmillan [Canada] ; Catherine C. Tenn [Canada] ; Lennard P. Niles [Canada] | Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease |
000716 |
Reyniel Cruz-Aguado [Canada] ; Daniella Winkler ; Christopher A. Shaw | Lack of behavioral and neuropathological effects of dietary β-methylamino-L-alanine (BMAA) in mice |
000722 |
Meenal Joshi [Canada] ; Rachel F. Tyndale [Canada] | Induction and recovery time course of rat brain CYP2E1 after nicotine treatment |
000731 |
N. M. Jadavji [Canada] ; B. Kolb [Canada] ; G. A. Metz [Canada] | Enriched environment improves motor function in intact and unilateral dopamine-depleted rats |
000737 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Claude Rouillard [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Daniel Levesque [Canada] | Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys |
000747 |
Maryka Quik [États-Unis] ; Neeraja Parameswaran [États-Unis] ; Sarah E. Mccallum [États-Unis] ; Tanuja Bordia [États-Unis] ; SHANSHAN BAO [États-Unis] ; Alison Mccormack [États-Unis] ; Amy Kim [États-Unis] ; Rachel F. Tyndale [Canada] ; J. William Langston [États-Unis] ; Donato A. Di Monte [États-Unis] | Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates |
000756 |
Fernanda G. De Souza [Brésil] ; Mayra D. B. Rodrigues [Brésil] ; Sergio Tufik [Brésil] ; José N. Nobrega [Canada] ; Vania D'Almeida [Brésil] | Acute stressor-selective effects on homocysteine metabolism and oxidative stress parameters in female rats |
000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
000758 |
J. Lewis [États-Unis] ; G. Bench [États-Unis] ; O. Myers [États-Unis] ; B. Tinner [Canada] ; W. Staines [Canada] ; E. Barr [États-Unis] ; K. K. Divine [États-Unis] ; W. Barrington [États-Unis] ; J. Karlsson [États-Unis] | Trigeminal uptake and clearance of inhaled manganese chloride in rats and mice |
000759 |
Jasvinder S. Sidhu [États-Unis] ; Yadavendra S. Rajawat [États-Unis] ; Tapan G. Rami [États-Unis] ; Michael H. Gollob [Canada] ; ZHINONG WANG [États-Unis] ; RUIYONG YUAN [États-Unis] ; A. J. Marian [États-Unis] ; Francesco J. Demayo [États-Unis] ; Donald Weilbacher [États-Unis] ; George E. Taffet [États-Unis] ; Joanna K. Davies [Royaume-Uni] ; David Carling [Royaume-Uni] ; Dirar S. Khoury [États-Unis] ; Robert Roberts [Canada] | Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome |
000784 |
Sarah A. Baker [États-Unis] ; Lianne E. Stanford [Canada] ; Richard E. Brown [Canada] ; Theo Hagg [États-Unis] | Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice |
000786 |
Wiplove Lamba [Canada] ; Wendy Prichett [Canada] ; David Munoz [Canada] ; David S. Park [Canada] ; John M. Woulfe [Canada] | MPTP induces intranuclear rodlet formation in midbrain dopaminergic neurons |
000798 |
J. M. B. Wilson [Canada] ; M. S. Petrik [Canada] ; M. H. Moghadasian [Canada] ; C. A. Shaw [Canada] | Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC |
000800 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
000803 |
Katerina Venderov [Canada] ; Timothy M. Brown [Royaume-Uni] ; Jonathan M. Brotchie [Canada] | Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus |
000809 |
Véronique Sgambato-Faure [France] ; Virginie Buggia [France] ; Frangois Gilbert [Canada] ; Daniel Levesque [Canada] ; Alim-Louis Benabid [France] ; Francois Berger [France] | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-lnduced behavioral sensitization in dyskinetic rats |
000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
000834 |
L. Clark [Royaume-Uni] ; R. Cools [Royaume-Uni] ; T. W. Robbins [Royaume-Uni] | The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning |
000839 |
Christopher J. Macdonald [États-Unis] ; Warren H. Meck [États-Unis] | Systems-level integration of interval timing and reaction time |
000850 |
Howard T. J. Mount [Canada] ; Jean-Claude Martel [France] ; Paul Fluit [Canada] ; YINGJI WU [Canada] ; Eleanor Gallo-Hendrikx [Canada] ; Cristina Cosi [France] ; Marc R. Marien [France] | Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia |
000861 |
D. J. Doudet [Canada] ; M. L. Cornfeldt [États-Unis] ; C. R. Honey [Canada] ; A. W. Schweikert [États-Unis] ; R. C. Allen [États-Unis] | PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease |
000866 |
Louise Normandin [Canada] ; Linda Ann Beaupre [Canada] ; Fariba Salehi [Canada] ; Annie St.-Pierre [Canada] ; Greg Kennedy [Canada] ; Donna Mergler [Canada] ; Roger F. Butterworth [Canada] ; Suzanne Philippe [Canada] ; Joseph Zayed [Canada] | Manganese distribution in the brain and neurobehavioral changes following inhalation exposure of rats to three chemical forms of manganese |
000879 |
Lynsey E. Bartlett [Canada] ; Damaso Sadi [Canada] ; Matthew Lewington [Canada] ; Ivar Mendez [Canada] ; Nicholas M. Boulis ; Charles Y. Liu ; Andres M. Lozano ; Roy A. E. Bakay | Functional improvement with low-dose dopaminergic grafts in hemiparkinsonian rats. Comments |
000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
000895 |
Kerry B. Goralski [Canada] ; Kenneth W. Renton [Canada] | Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats |
000909 |
Roger F. Butterworth [Canada] | Thiamin deficiency and brain disorders |
000914 |
Antonio P. Strafella [Canada] ; Tomas Paus [Canada] ; Maria Fraraccio [Canada] ; Alain Dagher [Canada] | Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex |
000921 |
K. Fuxe [Suède] ; L. F. Agnati [Italie] ; K. Jacobsen [Canada] ; J. Hillion [États-Unis] ; M. Canals [Espagne] ; M. Torvinen [Suède] ; B. Tinner-Staines [Canada] ; W. Staines [Canada] ; D. Rosin [États-Unis] ; A. Terasmaa [Suède] ; P. Popoli [Italie] ; G. Leo [Italie] ; V. Vergoni [Italie] ; C. Lluis [Espagne] ; F. Ciruela [Espagne] ; R. Franco [Espagne] ; S. Ferre [États-Unis] | Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease |
000926 |
Patrick L. Mcgeer [Canada] ; Claudia Schwab [Canada] ; Andre Parent [Canada] ; Doris Doudet [Canada] | Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration |
000933 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada] | Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems |
000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
000938 |
Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada] | Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease |
000950 |
LI LIU [Canada] ; Shu S. Hsu [Canada] ; Suneil K. Kalia [Canada] ; Andres M. Lozano [Canada] | Injury and strain-dependent dopaminergic neuronal degeneration in the substantia nigra of mice after axotomy or MPTP |
000951 |
Adam O. Hebb [Canada] ; Kari Hebb ; Arun C. Ramachandran ; Ivar Mendez | Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage |
000959 |
Benoit Melchior [France] ; Véronique Nerriere-Daguin [France] ; David-A. Laplaud [France] ; Séverine Remy [France] ; Sandrine Wiertlewski [France] ; Isabelle Neveu [France] ; Philippe Naveilhan [France] ; Susan O. Meakin [Canada] ; Philippe Brachet [France] | Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent neuroprotection |
000966 |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
000988 |
J. Q. Lu [Canada] ; A. J. Stoessl [Canada] | Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats |
000993 |
Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie] | Role of serotonin2C receptors in the control of brain dopaminergic function |
000A11 |
I. Khabazian [Canada] ; J. S. Bains [Canada] ; D. E. Williams [Canada] ; J. Cheung [Canada] ; J. M. B. Wilson [Canada] ; B. A. Pasqualotto [Canada] ; S. L. Pelech [Canada] ; R. J. Andersen [Canada] ; Y.-T. Wang [Canada] ; L. Liu [Canada] ; A. Nagai [Canada] ; S. U. Kim [Canada] ; U-K. Craig ; C. A. Shaw [Canada] | Isolation of various forms of sterol β-d-glucoside from the seed of Cycas circinalis: neurotoxicity and implications for ALS-parkinsonism dementia complex |
000A15 |
James E. Holden [États-Unis] ; Salma Jivan [Canada] ; Thomas J. Ruth [Canada] ; Doris J. Doudet [Canada] | In vivo receptor assay with multiple ligand concentrations: An equilibrium approach |
000A21 |
Sophie Callier [France, Canada] ; Maryvonne Le Saux [France] ; Anne-Marie Lhiaubet [France] ; Thérèse Di Paolo [Canada] ; William Rostene [France] ; Didier Pelaprat [France] | Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture |
000A22 |
Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease |
000A25 |
Kim G. C. Hellemans [Canada] ; Yavin Shaham [Canada] ; Mary C. Olmstead [Canada] | Effects of acute and prolonged opiate abstinence on extinction behaviour in rats |
000A42 |
Louise Normandin [Canada] ; Gaétan Carrier [Canada] ; Phillip F. Gardiner [Canada] ; Greg Kennedy [Canada] ; Alan S. Hazell [Canada] ; Donna Mergler [Canada] ; Roger F. Butterworth [Canada] ; Suzanne Philippe [Canada] ; Joseph Zayed [Canada] | Assessment of bioaccumulation, neuropathology, and neurobehavior following subchronic (90 days) inhalation in Sprague-Dawley rats exposed to manganese phosphate |
000A43 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
000A78 |
Doris J. Doudet [Canada] | Monitoring disease progression in Parkinson's disease |
000A83 |
A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada] | Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats |
000B08 |
A. R. Zahran [Canada] ; N. Simmerman [Canada] ; S. Carrier [Canada] ; P. Vachon [Canada] ; Y. Sato | Erectile dysfunction occurs following substantia nigra lesions in the rat. Commentary |
000B13 |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
000B14 |
Jun-Xia Xie [République populaire de Chine] ; MING TANG [République populaire de Chine] ; CHUNYI ZHANG [Canada] | Effect of cholecystokinin-8 microinjection into ventral tegmental area on dopamine release in nucleus accumbens of rats: An in vivo voltammetric study |
000B44 |
Y. L. Xue [République populaire de Chine] ; Z. F. Wang [République populaire de Chine] ; D. G. Zhong [République populaire de Chine] ; X. Cui [République populaire de Chine] ; X. J. Li [République populaire de Chine] ; X. J. Ma [République populaire de Chine] ; L. N. Wang [République populaire de Chine] ; K. Zhu [République populaire de Chine] ; A. M. Sun [Canada] | Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys |
000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
000B57 |
E. F. Field [Canada] ; I. Q. Whishaw [Canada] ; S. M. Pellis [Canada] | Sex differences in catalepsy : evidence for hormone-dependent postural mechanisms in haloperidol-treated rats |
000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
000B61 |
S. Miksys [Canada] ; Y. Rao [Canada] ; E. M. Sellers [Canada] ; M. Kwan [Canada] ; D. Mendis [Canada] ; R. F. Tyndale [Canada] | Regional and cellular distribution of CYP2D subfamily members in rat brain |
000B62 |
C. R. Honey [Canada] ; M. O. K. Obochi ; HAO SHEN ; P. Margaron ; S. Yip ; J. G. Levy | Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts |
000B68 |
M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice |
000B78 |
I. Mendez [Canada] ; M. Hong ; S. Smith ; A. Dagher ; J. Desrosiers | Neural transplantation cannula and microinjector system : experimental and clinical experience : Technical note |
000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
000B86 |
K. A. Baker [Canada] ; M. Hong [Canada] ; D. Sadi [Canada] ; I. Mendez [Canada] | Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease |
000B89 |
Maria C. Yang [Canada] ; Allan J. Mclean [Canada] ; Laurent P. Rivory [Australie] ; David G. Le Couteur [Canada] | Hepafic disposition of neurotoxins and pesticides |
000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
000B96 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
000C06 |
T. J. Hudzik [États-Unis] ; A. Howell [États-Unis] ; K. Payza [Canada] ; A. J. Cross [États-Unis] | Antiparkinson potential of δ-opioid receptor agonists |
000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
000C13 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
000C23 |
M. C. Evans [États-Unis] ; A. Pradhan [Canada] ; S. Venkatraman [États-Unis] ; W. H. Ojala [États-Unis] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α, α-disubstituted amino acids |
000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
000C33 |
A. F. Miranda [Canada] ; M. A. Sutton [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] ; R. J. Boegman [Canada] | Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus |
000C37 |
K. Kitani [Japon] ; S. Kanai [Japon] ; G. O. Ivy [Canada] ; M. C. Carrillo [Argentine] | Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl : a possible antioxidant strategy |
000C45 |
D. L. Gelowitz [États-Unis] ; I. A. Paterson [Canada] | Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration |
000C50 |
M. S. Kallos [Canada] ; L. A. Behie [Canada] | Inoculation and growth conditions for high-cell-density expansion of mammalian neural stem cells in suspension bioreactors |
000C53 |
G. D. Muir [Canada] ; I. Q. Whishaw [Canada] | Ground reaction forces in locomoting hemi-parkinsonian rats : a definitive test for impairments and compensations |
000C55 |
M. S. Kallos [Canada] ; L. A. Behie [Canada] ; A. L. Vescovi [Italie] | Extended serial passaging of mammalian Neural stem cells in suspension bioreactors |
000C56 |
T. Inoue [Canada, Japon] ; J. Tsui [Canada] ; N. Wong [Canada] ; SHIN YI WONG [Canada] ; F. Suzuki [Japon] ; YIN NAM KWOK [Canada] | Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment |
000C57 |
G. Flores [Mexique, Canada] ; J. J. Liang [Mexique, Canada] ; A. Sierra [Mexique] ; D. Martinez-Fong [Mexique] ; R. Quirion [Mexique, Canada] ; J. Aceves [Mexique] ; L. K. Srivastava [Mexique] | Expression of dopamine receptors in the subthalamic nucleus of the rat : Characterization using reverse transcriptase-polymerase chain reaction and autoradiography |
000C60 |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
000C62 |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
000C64 |
E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide |
000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
000C66 |
D. Frankel [Canada] ; H. M. Schipper [Canada] | Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury |
000C69 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content |
000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
000D10 |
E. G. Campioni [Canada] ; J. N. Nobrega [Canada] ; M. V. Sefton [Canada] | HEMA/MMMA microcapsule implants in hemiparkinsonian rat brain : Biocompatibility assessment using [3H]PK11195 as a marker for gliosis |
000D26 |
H. M. Schipper [Canada] ; R. Vininsky [Canada] ; R. Brull [Canada] ; L. Small [Canada] ; J. R. Brawer [Canada] | Astrocyte mitochondria : A substrate for iron deposition in the aging rat substantia nigra |
000D28 |
D. A. Loeffler [États-Unis] ; P. A. Lewitt [États-Unis] ; P. L. Juneau [États-Unis] ; D. M. Camp [États-Unis] ; A. J. Demaggio [États-Unis] ; P. Milbury [États-Unis] ; W. R. Matson [États-Unis] ; M. P. Rathbone [Canada] | Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover |
000D44 |
| Greffes |
000D52 |
A. Parent [Canada] ; L.-N. Hazrati [Canada] ; A. Charara [Canada] | The striatopallidal fiber system in primates |
000D59 |
R. Levy [France] ; L.-N. Hazrati [Canada] ; M.-T. Herrero [France, Espagne] ; M. Vila [France] ; O.-K. Hassani [France] ; M. Mouroux [France] ; M. Ruberg [France] ; H. Asensi [Espagne] ; Yves Agid [France] ; J. Feger [France] ; J. A. Obeso [Espagne] ; A. Parent [Canada] ; E. C. Hirsch [France] | Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states |
000D61 |
A. F. Miranda [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] | Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid |
000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
000D77 |
C. Thiffault [Canada] ; L. Lamarre-Theroux [Canada] ; R. Quirion [Canada] ; J. Poirier [Canada] | L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse |
000D78 |
N. A. Tatton [Canada] ; S. J. Kish [Canada] | In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and Acridine Orange Staining |
000D79 |
I. Q. Whishaw [Canada] ; B. L. K. Coles [Canada] ; S. M. Pellis [Canada] ; E. I. Miklyaeva [Canada] | Impairments and compensation in mouth and limb use in free feeding after unilateral dopamine depletions in a rat analog of human Parkinson's disease |
000D85 |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
000D93 |
P. W. Baures [États-Unis] ; W. H. Ojala [États-Unis] ; W. J. Costain [Canada] ; M. C. Ott [Canada] ; A. Pradhan [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide |
000E00 |
R. Kakkar [Canada] ; R. V. S. Raju [Canada] ; A. H. Rajput [Canada] ; R. K. Sharma [Canada] | Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme |
000E02 |
D. D. Newman [Canada] ; N. Rajakumar ; B. A. Flumerfelt ; A. J. Stoessl [Canada] | A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease |
000E07 |
MANOHAR LAL THAKUR [Canada] ; UMA SHANKAR SRIVASTAVA [Canada] | Vitamin-E metabolism and its application |
000E22 |
J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |
000E23 |
D. Boismenu [Canada] ; O. Mamer [Canada] ; L. Ste-Marie [Canada] ; L. Vachon [Canada] ; J. Montgomery [Canada] | In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors : Electrospray-MS analysis of intra-striatal microdialysates |
000E26 |
E. I. Miklyaeva [Canada] ; I. Q. Whishaw [Canada] | HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height |
000E28 |
M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada] | Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys |
000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
000E31 |
P. J. Blanchet [Canada] ; R. Grondin [Canada] ; P. J. Bedard [Canada] ; K. Shiosaki [États-Unis] ; D. R. Britton [États-Unis] | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates |
000E34 |
C. V. Borlongan [États-Unis] ; T. B. Freeman ; R. A. Hauser ; D. W. Cahill ; P. R. Sanberg ; R. R. Tasker | Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism : Relevance to neural transplantation. Commentary |
000E36 |
R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
000E40 |
B. P. Connop [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger ; K. Jhamandas [Canada] | Attenuation of malonate-induced degeneration of the nigrostriatal pathway by inhibitors of nitric oxide synthase |
000E48 |
J.-A. St-Pierre [Canada] ; P. J. Bedard | Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine |
000E56 |
S. A. L. Bennett [Canada] ; B. Stevenson ; W. A. Staines ; D. C. S. Roberts | Periodic acid-Schiff(PAS)-positive deposits in brain following kainic acid-induced seizures : relationships of fos induction, neuronal necrosis, reactive gliosis, and blood-brain barrier breakdown |
000E58 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
000E66 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
000E67 |
C. Thiffault [Canada] ; N. Aumont ; R. Quirion [Canada] ; J. Poirier | Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain |
000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
000E72 |
P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
000E73 |
G. M. Ross [Canada] ; B. E. Mccarry ; R. K. Mishra [Canada] | Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene |
000E81 |
XUDONG WANG [Canada] ; F. Manganaro ; H. M. Schipper | A cellular stress model for the sequestration of redox-active glial in the aging and degenerating nervous system |
000E88 |
E. Scarr [Canada] ; D. M. Wingerchuk ; A. V. Juorio ; I. A. Paterson | The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions |
000E93 |
M.-C. Asselin [Canada] ; J.-J. Soghomonian ; P.-Y. Côte ; A. Parent | Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys |
000E98 |
B. P. Connop [Canada] ; N. G. Rolfe ; R. J. Boegman [Canada] ; K. Jhamandas [Canada] ; R. J. Beninger | Potentiation of NMDA-mediated toxicity on nigrostriatal neurons by a low dose of 7-nitro indazole |
000F10 |
P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
000F36 |
M. Takada [Canada] ; T. Sugimoto ; T. Hattori [Canada] | MPTP neurotoxicity to cerebellar Purkinje cells in mice |
000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
000F46 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
000F57 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
000F61 |
| 3 rd Canadian conference on neurodegenerative diseases, L'Estérel PQ, April 4-6, 1991 |
000F70 |
H. A. Robertson [Canada] ; M. R. Peterson ; G. G. Worth | Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243 |
000F78 |
L. C. Doering [Canada] | Peripheral nerve segments promote consistent long-term survival of adrenal medulla transplants in the brain |
000F79 |
A. Tabatabaei [Canada] ; T. L. Perry ; S. Hansen ; C. Krieger | Partial protective effect of MK-4801 on MPTP-induced reduction of striatal dopamine in mice |
000F85 |
B. Lavoie [Canada] ; P.-Y. Cote ; A. Parent | Immunohistochemical study of the basal ganglia in normal and Parkinsonian monkeys |
000F89 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
000F91 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys |
000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
000F97 |
M. L. Paul [Canada] ; A. M. Graybiel ; J.-C. David ; H. A. Robertson [Canada] | D1-like and D2-like dopamine receptors synergistically actitave rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease |
001013 |
R. Rivest ; S. St-Pierre ; F. B. Jolicoeur | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat |
001015 |
W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
001025 |
R. Lemery ; TACK KI LEUNG ; E. Lavellee ; A. Girard ; M. Takajic ; D. Roy ; M. Montpetit | In vitro and in vivo effects within the coronary sinus of nonarcing an arcing shocks using a new system of low-energy DC ablation |
001026 |
F. B. Jolicoeur [Canada] ; R. Rivest ; A. Drumheller | Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat |
001029 |
M. Filion ; L. Tremblay ; P. J. Bedard | Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
001033 |
D. B. Calne ; M. J. Zigmond | Compensatory mechanisms in degenerative neurologic diseases : insights from Parkinsonism |
001037 |
F. B. Jolicoeur ; R. Rivest ; S. St.-Pierre ; A. Drumheller | Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats |
001040 |
M. Filion ; L. Tremblay | Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
001058 |
M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
001064 |
C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
001079 |
T. L. Perry ; C. Bergeron ; A. J. Biro ; S. Hansen | β-N-methylamino-L-alanine: chronic oral administration is not neurotoxic to mice |
001081 |
VOON WEE YONG ; M. Guttman ; S. U. Kim ; D. B. Calne ; I. Turnbull ; K. Watabe ; R. W. W. Tomlinson | Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms |
001093 |
G. S. Robertson ; D. G. Herrera ; M. Dragunow ; H. A. Robertson | L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra |
001096 |
P. J. Bedard ; R. Boucher | Effect of D1 receptor stimulation in normal and MPTP monkeys |
001097 |
C. Harnois ; G. Marcotte ; T. Di Paolo | Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence |
001126 |
P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
001161 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets |
001170 |
T. L. Perry ; VOON WEE YONG ; R. A. Wall ; K. Jones | Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse |
001182 |
M. Takada ; T. Hattori | Collateral projections from the substantia nigra to the cingulate cortex and striatum in the rat |
001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |